Zhang S X, Feng J, Kuo S C, Brossi A, Hamel E, Tropsha A, Lee K H
Natural Products Laboratory, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
J Med Chem. 2000 Jan 27;43(2):167-76. doi: 10.1021/jm990333a.
Inhibitors of tubulin polymerization interacting at the colchicine binding site are potential anticancer agents. We have been involved in the synthesis of a number of colchicine site agents, such as thiocolchicinoids and allocolchicinoids, which are colchicine analogues, and 2-phenyl-quinolones and 2-aryl-naphthyridinones, which are the amino analogues of cytotoxic antimitotic flavonoids. The most cytotoxic of the latter compounds strongly inhibit binding of radiolabeled colchicine to tubulin, and these agents therefore probably bind in the colchicine site of tubulin. We have applied conventional CoMFA and q(2)-GRS CoMFA to identify the essential structural requirements for increasing the ability of these compounds to form tubulin complexes. The CoMFA model for the training set of 51 compounds yielded cross-validated R(2) (q(2)) values of 0.637 for conventional CoMFA and 0.692 for q(2)-GRS CoMFA. The predictive power of this model was confirmed by successful activity prediction for a test set of 53 compounds with known potencies as inhibitors of tubulin polymerization. The activities of 88% of the compounds were predicted with absolute value of residuals of less than 0.5. The predictive q(2) values were 0.546 for conventional CoMFA and 0.426 for q(2)-GRS CoMFA. The conventional CoMFA model with the highest predictive q(2) (0.546) was analyzed in detail in terms of underlying structure-activity relationships.
在秋水仙碱结合位点相互作用的微管蛋白聚合抑制剂是潜在的抗癌药物。我们参与了多种秋水仙碱位点药物的合成,例如秋水仙碱类似物硫代秋水仙碱类化合物和别秋水仙碱类化合物,以及细胞毒性抗有丝分裂黄酮类化合物的氨基类似物2-苯基喹诺酮和2-芳基萘啶酮。后一类化合物中细胞毒性最强的能强烈抑制放射性标记的秋水仙碱与微管蛋白的结合,因此这些药物可能结合在微管蛋白的秋水仙碱位点。我们应用传统的比较分子场分析(CoMFA)和q(2)-广义回归比较分子场分析(q(2)-GRS CoMFA)来确定增强这些化合物形成微管蛋白复合物能力的基本结构要求。对于51种化合物的训练集,传统CoMFA的交叉验证R(2)(q(2))值为0.637,q(2)-GRS CoMFA的交叉验证R(2)(q(2))值为0.692。通过对53种已知作为微管蛋白聚合抑制剂效力的化合物测试集进行成功的活性预测,证实了该模型的预测能力。88%的化合物活性预测残差绝对值小于0.5。传统CoMFA的预测q(2)值为0.546,q(2)-GRS CoMFA的预测q(2)值为0.426。对具有最高预测q(2)(0.546)的传统CoMFA模型,根据潜在的构效关系进行了详细分析。